Chester County News and Community Website
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is betting on newly expanded reimbursement codes and emerging treatment applications for its XTRAC excimer laser to drive long-term growth, even …
STRATA Skin Sciences Eyes Growth from Expanded Reimbursement Despite Q2 Revenue Decline Read More
LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) posted second-quarter 2025 revenue of $2.88 million, up 100.3% from the same period last year, as demand for its branded products and contract …
NEXGEL Doubles Q2 Revenue, Targets $13M in 2025 With Positive EBITDA Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported a series of positive clinical milestones and second-quarter 2025 financial results, positioning its lead drug candidate, lorundrostat, for a potential new …
Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual …
Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported second-quarter 2025 revenue of $12.7 million, driven by continued commercial momentum for its lead product, YCANTH®, and milestone payments from …
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported second-quarter 2025 results alongside a series of major financing and regulatory developments that position the company to advance its …
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported encouraging early clinical results from its two lead oncology programs while narrowing its quarterly loss, according to second-quarter 2025 financial results …
Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …
Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) reported a strong second quarter for 2025, delivering $20.2 million in revenue, up 26% from the same period last year and 9% …
TELA Bio Posts Double-Digit Revenue Growth, Expands Product Reach in Q2 Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported a wider second-quarter loss as the company pressed forward with late-stage development of its lead cancer drug, firmonertinib, and advanced …
ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones Read More